I
107TH CONGRESS
2D SESSION
H. R. 5031
To expand research regarding inflammatory bowel disease, and for other
purposes.
IN THE HOUSE OF REPRESENTATIVES
JUNE 27, 2002
Mrs. KELLY (for herself, Mr. JACKSON of Illinois, and Mr. FLETCHER) intro-
duced the following bill; which was referred to the Committee on Energy
and Commerce
A BILL
To expand research regarding inflammatory bowel disease,
and for other purposes.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Inflammatory Bowel
Disease Act’’.
SEC. 2. FINDINGS.
Congress makes the following findings:
(1) Crohn’s disease and ulcerative colitis are se-
rious inflammatory diseases of the gastrointestinal
tract. Crohn’s disease may occur in any section of
SEC. 3. INFLAMMATORY BOWEL DISEASE RESEARCH EX-
PANSION.
(a) IN GENERAL.—The Director of the National In-
stitute of Diabetes and Digestive and Kidney Diseases
shall expand, intensify, and coordinate the activities of the
Institute with respect to research on inflammatory bowel
disease with particular emphasis on the following areas:
(1) Genetic research on susceptibility for in-
flammatory bowel disease, including the interaction
of genetic and environmental factors in the develop-
ment of the disease.
(2) Animal model research on inflammatory
bowel disease, including genetics in animals.
(3) Clinical inflammatory bowel disease re-
search, including clinical studies and treatment
trials.
(4) Other research initiatives identified by the
scientific document entitled ‘‘Challenges in Inflam-
matory Bowel Disease’’.
(b) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—For the purpose of carrying
out this section, there are authorized to be appro-
priated 
$75,000,000 
in 
fiscal 
year 
2003,
$100,000,000 in fiscal year 2004, and such sums as
may be necessary for fiscal years 2005 through
2006.
(2) RESERVATION.—Of the funds authorized to
be appropriated under paragraph (1), not more than
20 percent of such funds shall be reserved to fund
the training of qualified health professionals in bio-
medical research focused on inflammatory bowel dis-
ease and related disorders.
SEC. 4. INFLAMMATORY BOWEL DISEASE PREVENTION AND
EPIDEMIOLOGY.
(a) IN GENERAL.—The Director of the Centers for
Disease Control and Prevention shall establish a national
program of prevention and epidemiology to determine the
prevalence of inflammatory bowel disease in the United
States, and conduct public and professional awareness ac-
tivities on inflammatory bowel disease.
(b) AUTHORIZATION OF APPROPRIATIONS.—For the
purpose of carrying out this section, there are authorized
to be appropriated $5,000,000 in fiscal year 2003, and
such sums as may be necessary for fiscal years 2004
through 2006.
SEC. 5. STUDY OF INFLAMMATORY BOWEL DISEASE RE-
LATED SERVICES.
(a) IN GENERAL.—The Institute of Medicine of the
National Academics of Science shall conduct a study on
the coverage standards of medicare, medicaid, and the pri-
vate insurance market for the following therapies:
(1) Parenteral nutrition.
(2) Enteral nutrition formula.
(3) Medically necessary food products.
(4) Ostomy supplies.
(5) Therapies approved by the Food and Drug
Administration for Crohn’s disease and ulcerative
colitis.
(b) CONTENT.—The study shall also take into ac-
count the appropriate outpatient or home health care de-
livery settings.
(c) REPORT.—Not later than 6 months after the date
of enactment of this Act, the Institute of Medicine shall
submit a report to Congress describing the findings of the
study.
(d) AUTHORIZATION
OF APPROPRIATIONS.—There
are authorized to be appropriated to carry out this section,
such sums as may be necessary.
SEC. 6. SOCIAL SECURITY DISABILITY FOR INFLAMMATORY
BOWEL DISEASE PATIENTS.
(a) IN GENERAL.—The General Accounting Office
shall conduct a study of the problems patients encounter
when applying for disability insurance benefits under title
II of the Social Security Act. The study will also include
recommendations for improving the application process for
inflammatory bowel disease patients.
(b) REPORT.—Not later than 6 months after the date
of enactment of this Act, the General Accounting Office
shall submit a report to Congress describing the findings
of the study.
(c) AUTHORIZATION
OF APPROPRIATIONS.—There
are authorized to be appropriated to carry out this section,
such sums as may be necessary.
Æ